About Kuros Biosciences
Kuros Biosciences is a company based in Schlieren (Switzerland) founded in 2000. Kuros Biosciences has raised $24.65 million across 7 funding rounds from investors including Optiver, European Union and Life Sciences Partners. The company has 4 employees as of December 31, 2024. Kuros Biosciences has completed 1 acquisition, including Xpand Biotechnology. Kuros Biosciences offers products and services including MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules. Kuros Biosciences operates in a competitive market with competitors including OssDsign, ISTO Biologics, BONESUPPORT, Askel Healthcare and Renovos, among others.
- Headquarter Schlieren, Switzerland
- Employees 4 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kuros Biosciences Ltd.
-
Annual Revenue
$83.4 M (USD)125.11as on Dec 31, 2024
-
Net Profit
-$4.74 M (USD)68.75as on Dec 31, 2024
-
EBITDA
$2.84 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$24.65 M (USD)
in 7 rounds
-
Latest Funding Round
$6.24 M (USD), Post-IPO
Sep 07, 2022
-
Investors
Optiver
& 11 more
-
Employee Count
4
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kuros Biosciences
Kuros Biosciences is a publicly listed company on the SIX with ticker symbol KURN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Kuros Biosciences
Kuros Biosciences offers a comprehensive portfolio of products and services, including MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules.
Promotes bone growth for spinal fusions using advanced surface technology.
Provides flexible bone graft solution for surgical applications.
Enables predictable fusion in spinal procedures.
Supports bone regeneration in soft tissue environments.
Facilitates bone growth for fusion surgeries.
Funding Insights of Kuros Biosciences
Kuros Biosciences has successfully raised a total of $24.65M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.24 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kuros Biosciences
Kuros Biosciences has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Optiver, European Union and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
LifeCare Partners is involved in unspecified activities.
|
Locked | Locked | Locked | |
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked | |
|
Early-stage venture capital is invested in US and Europe.
|
Locked | Locked | Locked |
Investor details for Kuros Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kuros Biosciences
Kuros Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Xpand Biotechnology.
Investment portfolio details for Kuros Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Mini-bioreactors are developed as alternatives to 2D cell culture systems.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Kuros Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Kuros Biosciences
Detailed financials for Kuros Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kuros Biosciences Comparisons
Peer comparison for Kuros Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kuros Biosciences
Kuros Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OssDsign, ISTO Biologics, BONESUPPORT, Askel Healthcare and Renovos, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of regenerative 3D-printed orthopedic implants for craniofacial bone defects and trauma
|
|
| Locked | Locked | Locked |
Developer of treatments for cartilage and bone problems
|
|
| Locked | Locked | Locked |
Injectable synthetic bone substitutes are developed for fracture treatment.
|
|
| Locked | Locked | Locked |
Regenerative medicines for cartilage and bone tissue regeneration are developed.
|
|
| Locked | Locked | Locked |
Renovos is focused on regenerative medicine and therapeutic delivery.
|
Detailed competitors of Kuros Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kuros Biosciences
Complete news archive for Kuros Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kuros Biosciences
Kuros Biosciences was founded in 2000 and raised its 1st funding round 5 years after it was founded.
Kuros Biosciences is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Kuros Biosciences is a funded company, having raised a total of $24.65M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Kuros Biosciences is 4.
Annual revenue of Kuros Biosciences is $83.4M as on Dec 31, 2024.
Kuros Bioscience is a provider of smart solutions for bone disease management. It has developed solutions to improve patient rehabilitation. It provides a MagnetOs, a unique bone graft with submicron surface topography, that harnesses the power of osteoimmunology to deliver uniform, solid and stable spinal fusions. It has also developed a Fibrin-PTH candidate that delivers targeted and controlled bone formation. It promotes bone formation through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The device is in clinical trial 2A stage FDA approved.
Kuros Biosciences's top competitors include BONESUPPORT, OssDsign and Askel Healthcare.
Kuros Biosciences offers MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules.
Yes, Kuros Biosciences is publicly traded on SIX under the ticker symbol KURN.
Kuros Biosciences has made 1 acquisition, including Xpand Biotechnology.
Kuros Biosciences has 12 investors. Key investors include Optiver, European Union, Life Sciences Partners, LifeCare Partners, and VIP Partners.
The ticker symbol of Kuros Biosciences is KURN on SIX.